IASIS PHARMA announces the launch of the original antihypertensive pharmaceutical product under the brand name of Rami-Amlo®. The product is a fixed-dose combination of an Angiotensin Converting Enzyme (ACE) Inhibitor with a Calcium Channel Blocker.
Each Rami-Amlo® capsule, contains the active ingredients Ramipril & Amlodipine, combined in a single dosage form, in 4 strengths: 5mg / 5mg, 5mg / 10mg, 10mg / 5mg & 10mg / 10mg.
Rami-Amlo® is indicated as a substitution therapy for hypertensive patients effectively controlled by the concomitant administration of ramipril and amlodipine at the same dosage level.
Rami-Amlo® offers High Efficacy attributed to the combination of two well established antihypertensive drugs in a treatment scheme that demonstrates superiority over monotherapy and increases patient compliance and adherence to treatment.
Rami-Amlo® is available in a full strength range:
RAMI-AMLO® CAPS (10+10) MG/CAP
RAMI-AMLO® CAPS (10+5) MG/CAP
RAMI-AMLO® CAPS (5+10) MG/CAP
RAMI-AMLO® CAPS (5+5) MG/CAP
Pack size: 28 hard capsules.